




FIG. 1




FIG. 2




FIG. 3




FIG. 4




FIG. 5

6/31




FIG. 6




FIG. 7

8/31




FIG. 8

9/31

Split Antibody Pharmacokinetics




FIG. 9

10/31




FIG. 10

11/31




FIG. 11

12/31




FIG. 12




FIG. 13




FIG. 14




FIG. 15

16/31




FIG. 16




FIG. 17

18/31




FIG. 18




FIG. 19

20/31




FIG. 20




FIG. 21




FIG. 22




FIG. 23




FIG. 24




FIG. 26

rel. % max. response of DOTAM (DOTAM coupled with mono streptavidin)
Prodrugs A + B captured by <hFab> on surface in very high density
(Prit_1 RS as 100% reference)




FIG. 27

rel. % max. response of DOTAM (DOTAM coupled with mono streptavidin)
Solution of Prodrugs A + B captured on <hFab> surface in very high density
(Prit_1 RS as 100% reference)




FIG. 28

29/31




FIG. 29




FIG. 30




FIG. 31